(11) evaluating URAI, specifically Fiasp, and URLi, in patients with T1DM utilizing continuous subcutaneous insulin infusion (CSII) systems reported the superiority of URAI analogs over rapid-acting insulin analogs (RAIAs) in increasing time spent within normoglycemia (70–180 mg/dL). Here, INS is linked to type 1 diabetes mellitus.